Stem Cell Mobilization Peptides for Non-Invasive Collection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for collecting mesenchymal stem cells are invasive and inefficient, and these cells lose their proliferative ability and pluripotency when subcultured in vitro, making regenerative medicine using these cells challenging.
Innovation Solution
The use of nuclear proteins or fragment peptides thereof to mobilize mesenchymal stem cells into peripheral blood, which can then be collected and used for therapeutic purposes, overcoming the limitations of traditional cell collection methods and in vitro culturing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If bone marrow blood is collected using invasive techniques with thick needles inserted into the iliac bone, then mesenchymal stem cells can be obtained, but the donor experiences a large burden and discomfort
Solution Approach 1:
The patent uses G-CSF (granulocyte colony-stimulating factor) as an intermediary substance to stimulate the bone marrow to release mesenchymal stem cells into the peripheral blood. This mediator approach allows non-invasive collection of stem cells from peripheral blood instead of requiring invasive bone marrow aspiration, thereby reducing the burden on donors while still obtaining the desired stem cells
2Quantity of substance
If mesenchymal stem cells are subcultured continuously in vitro, then cell quantity increases, but the cells gradually lose their proliferative ability and pluripotency
Solution Approach 1:
The patent employs G-CSF administration as a preliminary action to mobilize mesenchymal stem cells from the bone marrow into the peripheral blood before collection. This allows the cells to be harvested in their native, undifferentiated state with full proliferative ability and pluripotency intact, avoiding the need for continuous in vitro subculturing that would otherwise cause loss of these critical properties
3Reliability
If high quality control is implemented to guarantee safety of in vivo transplantation, then special culture equipment such as CPC is required, but this limits the procedure to only a limited number of universities and companies
Solution Approach 1:
The patent replaces the complex mechanical system of specialized culture equipment (CPC facilities) with a pharmacological approach using G-CSF administration. This substitution allows stem cell collection through routine peripheral blood collection procedures that can be performed in standard clinical settings, thereby maintaining safety and quality control while eliminating the need for expensive, specialized infrastructure and making the technology accessible to broader medical facilities
Data Source
AI summary
The present inventors identified many nuclear proteins contained in the extract of skin tissue by mass spectrometry, randomly selected multiple partial amino acid sequences of the nuclear proteins, chemically synthesized peptides consisting of the partial amino acid sequences, and examined their activity of mobilizing mesenchymal stem cells. As a result, it was found that these multiple peptides show the activity of mobilizing mesenchymal stem cells into peripheral blood, even though their amino acid sequences are completely different from each other. The inventors also found that fragment peptides of the nuclear proteins have therapeutic effects on diseases characterized by inflammation and abnormalities of the immune system (e.g., inflammatory bowel disease and psoriasis). Based on these findings, a new regenerative medicine technology that can overcome the problems of cell transplantation therapy is provided.